Crystal structure of botulinum neurotoxin type A and implications for toxicity

被引:0
|
作者
D. Borden Lacy
William Tepp
Alona C. Cohen
Bibhuti R. DasGupta
Raymond C. Stevens
机构
[1] University of California,Department of Chemistry and Earnest Orlando Lawrence Berkeley National Laboratory
[2] University of Wisconsin,Department of Food Microbiology and Toxicology
来源
Nature Structural Biology | 1998年 / 5卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Botulinum neurotoxin type A (BoNT/A) is the potent disease agent in botulism, a potential biological weapon and an effective therapeutic drug for involuntary muscle disorders. The crystal structure of the entire 1,285 amino acid di-chain neurotoxin was determined at 3.3 Å resolution. The structure reveals that the translocation domain contains a central pair of αhelices 105 Å long and a ~50 residue loop or belt that wraps around the catalytic domain. This belt partially occludes a large channel leading to a buried, negative active site — a feature that calls for radically different inhibitor design strategies from those currently used. The fold of the translocation domain suggests a mechanism of pore formation different from other toxins. Lastly, the toxin appears as a hybrid of varied structural motifs and suggests a modular assembly of functional subunits to yield pathogenesis.
引用
收藏
页码:898 / 902
页数:4
相关论文
共 50 条
  • [31] Peripheral cholinergic specificity of botulinum type A neurotoxin
    Colasante, C.
    Morbiato, L.
    Paoli, M.
    Shone, C. C.
    Muraro, L.
    Sheikh, K.
    Rossetto, O.
    Montecucco, C.
    Molgo, J.
    TOXICON, 2013, 68 : 70 - 71
  • [32] Botulinum neurotoxin type A in neurogenic detrusor overactivity
    Boethig, R.
    Kaufmann, A.
    Bremer, J.
    Pannek, J.
    Domurath, B.
    UROLOGE, 2014, 53 (04): : 524 - 530
  • [33] Effects of purification on the bioavailability of botulinum neurotoxin type A
    Cheng, Luisa W.
    Onisko, Bruce
    Johnson, Eric A.
    Reader, J. Rachel
    Griffey, Stephen M.
    Larson, Ann E.
    Tepp, William H.
    Stanker, Larry H.
    Brandon, David L.
    Carter, J. Mark
    TOXICOLOGY, 2008, 249 (2-3) : 123 - 129
  • [34] The use of botulinum neurotoxin type A (BoNTA) in urology
    Apostolidis, A.
    Fowler, C. J.
    JOURNAL OF NEURAL TRANSMISSION, 2008, 115 (04) : 593 - 605
  • [35] Proteolysis of synthetic peptides by type A botulinum neurotoxin
    Schmidt, JJ
    Bostian, KA
    JOURNAL OF PROTEIN CHEMISTRY, 1995, 14 (08): : 703 - 708
  • [36] Rapid SERS Detection of Botulinum Neurotoxin Type A
    Subekin, Alexei
    Alieva, Rugiya
    Kukushkin, Vladimir
    Oleynikov, Ilya
    Zavyalova, Elena
    NANOMATERIALS, 2023, 13 (18)
  • [37] CHARACTERISTICS OF SUBUNITS OF THE BOTULINUM NEUROTOXIN TYPE-A
    VINOGRADOVA, ID
    UVAROVA, RN
    BARATOVA, LA
    KAZDOBINA, IS
    UGRYUMOVA, GA
    BULATOVA, TI
    IVANOV, KK
    BIOCHEMISTRY-MOSCOW, 1984, 49 (03) : 355 - 360
  • [38] Comparison of botulinum neurotoxin type A formulations in Asia
    Frevert, Juergen
    Ahn, Ki Young
    Park, Mee Young
    Sunga, Owen
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2018, 11 : 327 - 331
  • [39] Botulinum neurotoxin: A therapeutic powerhouse with broad clinical implications
    Aldridge, Jamie H. R.
    Brubaker, Mary Lou
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2023, 36 (04): : 39 - 41
  • [40] Variations in expression and release of botulinum neurotoxin in Clostridium botulinum type A strains
    Rao, Sphoorthy
    Starr, Renate L.
    Morris, Melissa G.
    Lin, Wei-Jen
    FOODBORNE PATHOGENS AND DISEASE, 2007, 4 (02) : 201 - 207